Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226

AIMS: In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)‐positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigating a possible drug interaction between anastrozo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Hertz, Daniel L., Barlow, William E., Kidwell, Kelley M., Albain, Kathy S., Vandenberg, Ted A., Dakhil, Shaker R., Tirumali, Nagendra R., Livingston, Robert B., Gralow, Julie, Hayes, Daniel F., Hortobagyi, Gabriel N., Mehta, Rita S., Rae, James M.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Drug Interactions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876171/
https://ncbi.nlm.nih.gov/pubmed/26859101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12904
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares